Cargando…
Tissue‐specific variation in nonsense mutant transcript level and drug‐induced read‐through efficiency in the Cln1 (R151X) mouse model of INCL
About 10% of inherited diseases are caused by nonsense mutations [Trends Mol Med 18 (2012) 688], and nonsense suppression drug therapy promoting translation through premature stop codons is an emerging therapeutic approach. Infantile neuronal ceroid lipofuscinosis (INCL), a childhood neurodegenerati...
Autores principales: | Thada, Vaughn, Miller, Jake N., Kovács, Attila D., Pearce, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727554/ https://www.ncbi.nlm.nih.gov/pubmed/26648046 http://dx.doi.org/10.1111/jcmm.12744 |
Ejemplares similares
-
A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies
por: Geraets, Ryan D., et al.
Publicado: (2017) -
A tailored Cln3(Q352X) mouse model for testing therapeutic interventions in CLN3 Batten disease
por: Langin, Logan, et al.
Publicado: (2020) -
Mice homozygous for c.451C>T mutation in Cln1 gene recapitulate INCL phenotype
por: Bouchelion, Ashleigh, et al.
Publicado: (2014) -
Nonsense Mutation in Coiled-Coil Domain Containing 151 Gene (CCDC151) Causes Primary Ciliary Dyskinesia
por: Alsaadi, Muslim M, et al.
Publicado: (2014) -
Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender
por: Kovács, Attila D., et al.
Publicado: (2015)